Specifically, this study looked at the odds ratios for overall survival (OS) and disease free survival (DFS) at 3 and 5 years for patients with AR expression, in which 4658 patients (60.5%) had breast cancers that were notably AR-positive. The gene discussed is AR; the disease is breast cancer.